Company: AZN
Filing Date: 2025-07-29
Form Type: 6-K
Source: 0001104659-25-071432
Chunk: 1

Company: ASTRAZENECA PLC
Filing Date: 2025-07-29
Form: 6-K
Chunk 1
---
13,795 |   |       11 |   |  10 |
| - Alliance Revenue    |   | ​       |  1,293 |   |       38 |   |   38 | ​ |   | ​       |    654 |   |       36 |   |  35 |
| Product Revenue2      | ​ | ​       | 27,963 | ​ |        9 | ​ |   11 | ​ | ​ | ​       | 14,449 | ​ |       12 | ​ |  11 |
| Collaboration Revenue |   | ​       |     82 |   |       68 |   |   66 | ​ |   | ​       |      8 |   |      >2x |   | >2x |
| Total Revenue         |   | ​       | 28,045 |   |        9 |   |   11 | ​ |   | ​       | 14,457 |   |       12 |   |  11 |
| Reported EPS ($)      | ​ | ​       |   3.46 |   |       31 |   |   32 | ​ | ​ | ​       |   1.58 |   |       27 |   |  31 |
| Core3 EPS ($)         | ​ | ​       |   4.66 |   |       16 |   |   17 | ​ | ​ | ​       |   2.17 |   |       10 |   |  12 |

Key performance elements for H1 2025 (Growth numbers at constant exchange rates)

| ‒ | Total Revenue up 11% to $28,045m, driven by double-digit growth in Oncology and BioPharmaceuticals |

| ‒ | Growth in Total Revenue across all major geographic regions |

| ‒ | Core Operating profit increased 13% |

| ‒ | Core EPS increased 17% to $4.66 |

| ‒ | 12 positive Phase III readouts and 19 approvals in major regions |

| ‒ | Interim dividend increased 3% to $1.03 (76.7 pence, 9.81 SEK) |

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has